ArticleVaccines2021

The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom.

Michele A Kohli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.